THE STRATIFIED MICRO-RANDOMIZED TRIAL DESIGN: SAMPLE SIZE CONSIDERATIONS FOR TESTING NESTED CAUSAL EFFECTS OF TIME-VARYING TREATMENTS.
Ontology highlight
ABSTRACT:
SUBMITTER: Dempsey W
PROVIDER: S-EPMC8049613 | biostudies-literature |
REPOSITORIES: biostudies-literature
Similar Datasets
Project description:Individuals differ in how they respond to a particular treatment or exposure, and social scientists are often interested in understanding how treatment effects are moderated by observed characteristics of individuals. Effect moderation occurs when individual covariates dampen or amplify the effect of some exposure. This article focuses on estimating moderated causal effects in longitudinal settings where both the treatment and effect moderator vary over time. Effect moderation is typically examined using covariate by treatment interactions in regression analyses, but in the longitudinal setting, this approach may be problematic because time-varying moderators of future treatment may be affected by prior treatment-for example, moderators may also be mediators-and naively conditioning on an outcome of treatment in a conventional regression model can lead to bias. This article introduces to sociology moderated intermediate causal effects and the structural nested mean model for analyzing effect moderation in the longitudinal setting. It discusses problems with conventional regression and presents a new approach to estimation that avoids these problems (regression-with-residuals). The method is illustrated using longitudinal data from the PSID to examine whether the effects of time-varying exposures to poor neighborhoods on the risk of adolescent childbearing are moderated by time-varying family income.
| S-EPMC5788466 | biostudies-literature
Project description:The case-cohort (CC) study design usually has been used for risk factor assessment in epidemiologic studies or disease prevention trials for rare diseases. The sample size/power calculation for a stratified CC (SCC) design has not been addressed before. This article derives such result based on a stratified test statistic. Simulation studies show that the proposed test for the SCC design utilizing small sub-cohort sampling fractions is valid and efficient for situations where the disease rate is low. Furthermore, optimization of sampling in the SCC design is discussed and compared with proportional and balanced sampling techniques. An epidemiological study is provided to illustrate the sample size calculation under the SCC design.
| S-EPMC4159408 | biostudies-other
Project description:BackgroundPrevious research on educational data has demonstrated that Rasch fit statistics (mean squares and t-statistics) are highly susceptible to sample size variation for dichotomously scored rating data, although little is known about this relationship for polytomous data. These statistics help inform researchers about how well items fit to a unidimensional latent trait, and are an important adjunct to modern psychometrics. Given the increasing use of Rasch models in health research the purpose of this study was therefore to explore the relationship between fit statistics and sample size for polytomous data.MethodsData were collated from a heterogeneous sample of cancer patients (n = 4072) who had completed both the Patient Health Questionnaire - 9 and the Hospital Anxiety and Depression Scale. Ten samples were drawn with replacement for each of eight sample sizes (n = 25 to n = 3200). The Rating and Partial Credit Models were applied and the mean square and t-fit statistics (infit/outfit) derived for each model.ResultsThe results demonstrated that t-statistics were highly sensitive to sample size, whereas mean square statistics remained relatively stable for polytomous data.ConclusionIt was concluded that mean square statistics were relatively independent of sample size for polytomous data and that misfit to the model could be identified using published recommended ranges.
| S-EPMC2440760 | biostudies-literature
Project description:Multinomial Logistic Regression (MLR) has been advocated for developing clinical prediction models that distinguish between three or more unordered outcomes. We present a full-factorial simulation study to examine the predictive performance of MLR models in relation to the relative size of outcome categories, number of predictors and the number of events per variable. It is shown that MLR estimated by Maximum Likelihood yields overfitted prediction models in small to medium sized data. In most cases, the calibration and overall predictive performance of the multinomial prediction model is improved by using penalized MLR. Our simulation study also highlights the importance of events per variable in the multinomial context as well as the total sample size. As expected, our study demonstrates the need for optimism correction of the predictive performance measures when developing the multinomial logistic prediction model. We recommend the use of penalized MLR when prediction models are developed in small data sets or in medium sized data sets with a small total sample size (ie, when the sizes of the outcome categories are balanced). Finally, we present a case study in which we illustrate the development and validation of penalized and unpenalized multinomial prediction models for predicting malignancy of ovarian cancer.
| S-EPMC6590172 | biostudies-literature
Project description:This paper presents methods to calculate sample size for evaluating mediation by joint testing of both links in an indirect pathway from exposure to mediator to outcome. Calculations rely on simulations of the underlying data structure, with testing of the two links performed under the simplifying assumption that the two test statistics are asymptotically independent. Simulations show that the proposed methods are accurate. Continuous and binary exposures and mediators, as well as continuous, binary, count, and survival outcomes are accommodated, along with over-dispersion of count outcomes, design effects, and confounding of the exposure-mediator and mediator-outcome relationships. An illustrative example is provided, and a documented R program implementing the calculations is available online.
| S-EPMC4442753 | biostudies-literature
Project description:Individual randomized trials (IRTs) and cluster randomized trials (CRTs) with binary outcomes arise in a variety of settings and are often analyzed by logistic regression (fitted using generalized estimating equations for CRTs). The effect of stratification on the required sample size is less well understood for trials with binary outcomes than for continuous outcomes. We propose easy-to-use methods for sample size estimation for stratified IRTs and CRTs and demonstrate the use of these methods for a tuberculosis prevention CRT currently being planned. For both IRTs and CRTs, we also identify the ratio of the sample size for a stratified trial vs a comparably powered unstratified trial, allowing investigators to evaluate how stratification will affect the required sample size when planning a trial. For CRTs, these can be used when the investigator has estimates of the within-stratum intracluster correlation coefficients (ICCs) or by assuming a common within-stratum ICC. Using these methods, we describe scenarios where stratification may have a practically important impact on the required sample size. We find that in the two-stratum case, for both IRTs and for CRTs with very small cluster sizes, there are unlikely to be plausible scenarios in which an important sample size reduction is achieved when the overall probability of a subject experiencing the event of interest is low. When the probability of events is not small, or when cluster sizes are large, however, there are scenarios where practically important reductions in sample size result from stratification.
| S-EPMC7247053 | biostudies-literature
Project description:Factorial experimental designs have many potential advantages for behavioral scientists. For example, such designs may be useful in building more potent interventions by helping investigators to screen several candidate intervention components simultaneously and to decide which are likely to offer greater benefit before evaluating the intervention as a whole. However, sample size and power considerations may challenge investigators attempting to apply such designs, especially when the population of interest is multilevel (e.g., when students are nested within schools, or when employees are nested within organizations). In this article, we examine the feasibility of factorial experimental designs with multiple factors in a multilevel, clustered setting (i.e., of multilevel, multifactor experiments). We conduct Monte Carlo simulations to demonstrate how design elements-such as the number of clusters, the number of lower-level units, and the intraclass correlation-affect power. Our results suggest that multilevel, multifactor experiments are feasible for factor-screening purposes because of the economical properties of complete and fractional factorial experimental designs. We also discuss resources for sample size planning and power estimation for multilevel factorial experiments. These results are discussed from a resource management perspective, in which the goal is to choose a design that maximizes the scientific benefit using the resources available for an investigation.
| S-EPMC3351535 | biostudies-literature
Project description:BACKGROUND/AIMS:Clinical trials for Alzheimer's disease have been aimed primarily at persons who have cognitive symptoms at enrollment. However, researchers are now recognizing that the pathophysiological process of Alzheimer's disease begins years, if not decades, prior to the onset of clinical symptoms. Successful intervention may require intervening early in the disease process. Critical issues arise in designing clinical trials for primary and secondary prevention of Alzheimer's disease including determination of sample sizes and follow-up duration. We address a number of these issues through application of a unifying multistate model for the preclinical course of Alzheimer's disease. A multistate model allows us to specify at which points during the long disease process the intervention exerts its effects. METHODS:We used a nonhomogeneous Markov multistate model for the progression of Alzheimer's disease through preclinical disease states defined by biomarkers, mild cognitive impairment and Alzheimer's disease dementia. We used transition probabilities based on several published cohort studies. Sample size methods were developed that account for factors including the initial preclinical disease state of trial participants, the primary endpoint, age-dependent transition and mortality rates and specifications of which transition rates are the targets of the intervention. RESULTS:We find that Alzheimer's disease prevention trials with a clinical primary endpoint of mild cognitive impairment or Alzheimer's disease dementia will require sample sizes of the order many thousands of individuals with at least 5 years of follow-up, which is larger than most Alzheimer's disease therapeutic trials conducted to date. The reasons for the large trial sizes include the long and variable preclinical period that spans decades, high rates of attrition among elderly populations due to mortality and losses to follow-up and potential selection effects, whereby healthier subjects enroll in prevention trials. A web application is available to perform sample size calculations using the methods reported here. CONCLUSION:Sample sizes based on multistate models can account for the points in the disease process when interventions exert their effects and may lead to more accurate sample size determinations. We will need innovative strategies to help design Alzheimer's disease prevention trials with feasible sample size requirements and durations of follow-up.
| S-EPMC6442939 | biostudies-literature
Project description:Mid-study design modifications are becoming increasingly accepted in confirmatory clinical trials, so long as appropriate methods are applied such that error rates are controlled. It is therefore unfortunate that the important case of time-to-event endpoints is not easily handled by the standard theory. We analyze current methods that allow design modifications to be based on the full interim data, i.e., not only the observed event times but also secondary endpoint and safety data from patients who are yet to have an event. We show that the final test statistic may ignore a substantial subset of the observed event times. An alternative test incorporating all event times is found, where a conservative assumption must be made in order to guarantee type I error control. We examine the power of this approach using the example of a clinical trial comparing two cancer therapies.
| S-EPMC4749572 | biostudies-literature
Project description:Rising medical costs are an emerging challenge in policy decisions and resource allocation planning. When cumulative medical cost is the outcome, right-censoring induces informative missingness due to heterogeneity in cost accumulation rates across subjects. Inverse-weighting approaches have been developed to address the challenge of informative cost trajectories in mean cost estimation, though these approaches generally ignore post-baseline treatment changes. In post-hysterectomy endometrial cancer patients, data from a linked database of Medicare records and the Surveillance, Epidemiology, and End Results program of the National Cancer Institute reveal substantial within-subject variation in treatment over time. In such a setting, the utility of existing intent-to-treat approaches is generally limited. Estimates of population mean cost under a hypothetical time-varying treatment regime can better assist with resource allocation when planning for a treatment policy change; such estimates must inherently take time-dependent treatment and confounding into account. In this paper, we develop a nested g-computation approach to cost analysis to address this challenge, while accounting for censoring. We develop a procedure to evaluate sensitivity to departures from baseline treatment ignorability. We further conduct a variety of simulations and apply our nested g-computation procedure to two-year costs from endometrial cancer patients.
| S-EPMC8186489 | biostudies-literature